Vekic Jelena, Zeljkovic Aleksandra, Al Rasadi Khalid, Cesur Mustafa, Silva-Nunes José, Stoian Anca Pantea, Rizzo Manfredi
Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
Medical Research Center, Sultan Qaboos University, Muscat 123, Oman.
Metabolites. 2022 Jan 24;12(2):108. doi: 10.3390/metabo12020108.
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk.
残余心血管疾病（CVD）风险的存在是当前临床实践中的一个难题；事实上，尽管进行了最佳管理和治疗，但仍有相当一部分患者发生重大心血管事件。新型脂蛋白生物标志物被认为是改善CVD高危患者预后的可能靶点，此前已对其对重大心血管事件和死亡率的影响进行了研究。创新的抗糖尿病疗法最近显示，除了对血糖参数的影响外，还能显著降低致动脉粥样硬化脂蛋白；也有人认为，这种抗动脉粥样硬化作用可能是至少一些新型抗糖尿病药物（如胰高血糖素样肽-1受体激动剂）心血管获益的有价值的机制解释。这强调了该领域需要进一步研究，以便清楚地评估创新治疗对不同新型生物标志物的影响，包括致动脉粥样硬化脂蛋白，如小而密低密度脂蛋白（LDL）、脂蛋白（a）[Lp（a）]和功能失调的高密度脂蛋白（HDL）。本文讨论了新型脂质生物标志物对更好地管理患者以克服残余心血管风险的临床重要性。
